Wealthcare Capital Partners LLC Takes Position in Eli Lilly and Company $LLY

Key Points

• Wealthcare Capital Partners LLC has purchased a new position in Eli Lilly and Company, acquiring 328 shares valued at approximately $256,000 in the second quarter.
• Major institutional investors have significantly increased their stakes in Eli Lilly, with PNC Financial Services Group boosting its shares by 97.5% and Cohen Investment Advisors raising theirs by 7,975.5% in the first quarter.
• Analysts have recently revised their price targets for Eli Lilly, with UBS Group lowering its target from $1,050 to $895, while the consensus rating remains a "Moderate Buy."

Wealthcare Capital Partners LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 328 shares of the company's stock, valued at approximately $256,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in LLY. PNC Financial Services Group Inc. increased its stake in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after buying an additional 50,002,551 shares during the last quarter. Nuveen LLC bought a new stake in shares of Eli Lilly and Company in the first quarter worth $4,613,912,000. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Cohen Investment Advisors LLC increased its stake in Eli Lilly and Company by 7,975.5% during the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after purchasing an additional 773,947 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock valued at $1,154,508,000 after purchasing an additional 765,010 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In related news, EVP Daniel Skovronsky acquired 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $840.46 on Friday. The company has a market capitalization of $795.47 billion, a P/E ratio of 54.93, a PEG ratio of 1.17 and a beta of 0.47. The company has a 50-day simple moving average of $734.60 and a 200 day simple moving average of $765.98. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on LLY. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Guggenheim lowered their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. Morgan Stanley lowered their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research note on Friday. Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, Berenberg Bank reiterated a "hold" rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $938.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.